Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-101 vaccine in kidney transplant candidates
NCT03629080Phase 2Completed
- Sponsor
- HOOKIPA Pharma
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of HB-101 in cytomegalovirus infection (CMV) (6 arms), sponsored by HOOKIPA Pharma. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 15 months, Assessment of Humoral Immunogenicity Analyses at 15 months and 3 more. Started Dec 2018; status: completed.
02
Drugs
HB-101
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03629080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629080.